RxDoctor Payments Data

Angela Villatoro

Family · Bakersfield, CANPI 1497941611

Payments from drug & device makers

$928in general payments, 2019–2025

Across 35 payments — averaging $26.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$274
  • Lilly USA, LLC$195
  • Bayer$125
  • Gilead$49
  • Amgen$45
  • Coloplast$41
  • plus $199 from 8 others

What the payments were for

  • Food & beverage$928100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$928 in reported general payments places this provider in the 70th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$176
Medicare patients
19
Services billed
29

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide50$68,299
JardianceEmpagliflozin42$61,277
OzempicSemaglutide52$56,706
FarxigaDapagliflozin Propanediol45$47,331
Atorvastatin Calcium220$1,835
Albuterol Sulfate HfaAlbuterol Sulfate45$1,362
Ventolin HfaAlbuterol Sulfate21$1,167
Lisinopril150$978
Metformin Hcl123$878
Gabapentin71$466
Amlodipine Besylate71$322
Simvastatin38$319
Levothyroxine Sodium48$316
Montelukast Sodium22$315
Escitalopram Oxalate17$300

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$274$125,006102 claims
AstraZenecaFarxiga$19$47,33145 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,634 family providers in California.

Other family in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →